SG11202000250PA - A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers - Google Patents
A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancersInfo
- Publication number
- SG11202000250PA SG11202000250PA SG11202000250PA SG11202000250PA SG11202000250PA SG 11202000250P A SG11202000250P A SG 11202000250PA SG 11202000250P A SG11202000250P A SG 11202000250PA SG 11202000250P A SG11202000250P A SG 11202000250PA SG 11202000250P A SG11202000250P A SG 11202000250PA
- Authority
- SG
- Singapore
- Prior art keywords
- msi
- cancers
- prevention
- treatment
- vaccine based
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 108091092878 Microsatellite Proteins 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17181026 | 2017-07-12 | ||
| PCT/EP2018/069032 WO2019012082A1 (en) | 2017-07-12 | 2018-07-12 | UNIVERSAL VACCINE BASED ON SHARED TUMOR NEO-ANTIGENS FOR THE PREVENTION AND TREATMENT OF MICRO-SATELLITE INSTABILITY CANCER (MSI) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000250PA true SG11202000250PA (en) | 2020-02-27 |
Family
ID=59366234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000250PA SG11202000250PA (en) | 2017-07-12 | 2018-07-12 | A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11578109B2 (enExample) |
| EP (1) | EP3652606B1 (enExample) |
| JP (1) | JP7274223B2 (enExample) |
| KR (1) | KR102709778B1 (enExample) |
| CN (1) | CN111328420B (enExample) |
| AU (1) | AU2018298849B2 (enExample) |
| BR (1) | BR112020000590A2 (enExample) |
| CA (1) | CA3069047A1 (enExample) |
| DK (1) | DK3652606T5 (enExample) |
| ES (1) | ES2940087T3 (enExample) |
| FI (1) | FI3652606T3 (enExample) |
| HU (1) | HUE061840T2 (enExample) |
| IL (1) | IL271966B2 (enExample) |
| MX (1) | MX2020000413A (enExample) |
| NZ (1) | NZ759940A (enExample) |
| PL (1) | PL3652606T3 (enExample) |
| PT (1) | PT3652606T (enExample) |
| SG (1) | SG11202000250PA (enExample) |
| WO (1) | WO2019012082A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020022897A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| EP3827265A1 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Cancer vaccines for kidney cancer |
| IL321692A (en) | 2018-07-26 | 2025-08-01 | Curevac Netherlands B V | Cancer vaccines for colorectal cancer |
| US20210162032A1 (en) | 2018-07-26 | 2021-06-03 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| WO2020022901A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for uterine cancer |
| US20210252123A1 (en) | 2018-07-26 | 2021-08-19 | Frame Pharmaceuticals B.V. | ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020163802A1 (en) * | 2019-02-07 | 2020-08-13 | Arizona Board Of Regents On Behalf Of Arizona State University | Cancer specific frameshift vaccines |
| CA3161800A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| US20230212243A1 (en) * | 2020-05-12 | 2023-07-06 | Institut Curie | Neoantigenic Epitopes Associated with SF3B1 Mutations |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| US20240218019A1 (en) * | 2021-04-06 | 2024-07-04 | Board Of Regents, The University Of Texas System | Methods and compositions comprising mhc class i peptides |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922315A (en) | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
| US8053552B2 (en) * | 2002-04-18 | 2011-11-08 | Mtm Laboratories, Ag | Neopeptides and methods useful for detection and treatment of cancer |
| US20060160090A1 (en) * | 2003-04-11 | 2006-07-20 | Macina Robert A | Composition splice variants and methods relating to cancer specific genes and proteins |
| CN1824325A (zh) * | 2005-12-16 | 2006-08-30 | 武汉大学 | 人乳头病毒dna嵌合疫苗及制备方法和应用 |
| KR101454287B1 (ko) * | 2006-10-17 | 2014-11-04 | 온코세라피 사이언스 가부시키가이샤 | Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신 |
| TW201102081A (en) * | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
| AU2010252939B2 (en) | 2009-05-29 | 2014-06-26 | Morphosys Ag | A collection and methods for its use |
| MX2012011668A (es) * | 2010-04-09 | 2012-12-17 | Oncotherapy Science Inc | Peptidos cdca5 y vacunas que incluyen los mismos. |
| AU2012230259B2 (en) * | 2011-03-24 | 2017-04-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Dominant negative HSP110 mutant and its use in prognosing and treating cancers |
| BR112014001363B1 (pt) * | 2011-08-12 | 2021-06-01 | Oncotherapy Science, Inc. | Composições para indução de um linfócito t citotóxico (ctl), para indução de uma célula apresentadora de antígeno (apc) tendo capacidade de indução de ctl, composição farmacêutica, métodos in vitro para indução de apc e de ctl, usos de peptídeos e vetor |
| JP5890769B2 (ja) * | 2012-12-13 | 2016-03-22 | ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ | がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ） |
| WO2014090265A1 (en) * | 2012-12-13 | 2014-06-19 | Ruprecht-Karls-Universität Heidelberg | Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer |
| US9205140B2 (en) * | 2012-12-13 | 2015-12-08 | Ruprecht-Karls-Universität | MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer |
| WO2014099979A2 (en) * | 2012-12-17 | 2014-06-26 | Virginia Tech Intellectual Properties, Inc. | Methods and compositions for identifying global microsatellite instability and for characterizing informative microsatellite loci |
| US11098367B2 (en) * | 2014-01-27 | 2021-08-24 | Yale University | Methods of identifying patients responsive to immunotherapeutic strategies |
| CN108025048B (zh) * | 2015-05-20 | 2022-10-25 | 博德研究所 | 共有的新抗原 |
| CN106350578A (zh) * | 2015-07-13 | 2017-01-25 | 中国人民解放军第二军医大学 | Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用 |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
-
2018
- 2018-07-12 BR BR112020000590-8A patent/BR112020000590A2/pt unknown
- 2018-07-12 CA CA3069047A patent/CA3069047A1/en active Pending
- 2018-07-12 JP JP2020501311A patent/JP7274223B2/ja active Active
- 2018-07-12 HU HUE18742985A patent/HUE061840T2/hu unknown
- 2018-07-12 NZ NZ759940A patent/NZ759940A/en unknown
- 2018-07-12 DK DK18742985.7T patent/DK3652606T5/da active
- 2018-07-12 KR KR1020207000642A patent/KR102709778B1/ko active Active
- 2018-07-12 CN CN201880046801.8A patent/CN111328420B/zh active Active
- 2018-07-12 US US16/626,458 patent/US11578109B2/en active Active
- 2018-07-12 WO PCT/EP2018/069032 patent/WO2019012082A1/en not_active Ceased
- 2018-07-12 AU AU2018298849A patent/AU2018298849B2/en active Active
- 2018-07-12 MX MX2020000413A patent/MX2020000413A/es unknown
- 2018-07-12 EP EP18742985.7A patent/EP3652606B1/en active Active
- 2018-07-12 SG SG11202000250PA patent/SG11202000250PA/en unknown
- 2018-07-12 PT PT187429857T patent/PT3652606T/pt unknown
- 2018-07-12 FI FIEP18742985.7T patent/FI3652606T3/fi active
- 2018-07-12 PL PL18742985.7T patent/PL3652606T3/pl unknown
- 2018-07-12 IL IL271966A patent/IL271966B2/en unknown
- 2018-07-12 ES ES18742985T patent/ES2940087T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3069047A1 (en) | 2019-01-17 |
| KR20200029443A (ko) | 2020-03-18 |
| WO2019012082A9 (en) | 2019-05-02 |
| EP3652606A1 (en) | 2020-05-20 |
| PT3652606T (pt) | 2023-03-16 |
| CN111328420B (zh) | 2023-07-25 |
| WO2019012082A1 (en) | 2019-01-17 |
| MX2020000413A (es) | 2020-09-28 |
| DK3652606T5 (da) | 2024-08-26 |
| AU2018298849A1 (en) | 2020-01-02 |
| FI3652606T3 (fi) | 2023-03-16 |
| CN111328420A (zh) | 2020-06-23 |
| IL271966A (en) | 2020-02-27 |
| HUE061840T2 (hu) | 2023-08-28 |
| JP7274223B2 (ja) | 2023-05-16 |
| DK3652606T3 (da) | 2023-03-13 |
| ES2940087T3 (es) | 2023-05-03 |
| RU2019144505A (ru) | 2021-08-12 |
| BR112020000590A2 (pt) | 2020-07-14 |
| IL271966B1 (en) | 2024-09-01 |
| JP2020532288A (ja) | 2020-11-12 |
| NZ759940A (en) | 2023-07-28 |
| PL3652606T3 (pl) | 2023-04-24 |
| EP3652606B1 (en) | 2023-01-11 |
| US11578109B2 (en) | 2023-02-14 |
| US20200222519A1 (en) | 2020-07-16 |
| RU2019144505A3 (enExample) | 2021-08-12 |
| IL271966B2 (en) | 2025-01-01 |
| KR102709778B1 (ko) | 2024-09-26 |
| AU2018298849B2 (en) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271966A (en) | A universal vaccine based on common neoantigens for the prevention and treatment of cancer (MICRO SATELLITE INSTABLE (MSI) | |
| IL255333A0 (en) | Vaccines for the treatment and prevention of cancer | |
| GB2604416B (en) | Tumor infiltating lymphocytes and methods of therapy | |
| ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
| IL253243A0 (en) | Combined preparations for the treatment of cancer or infection | |
| IL267795A (en) | Combined treatment for cancer | |
| SI3458052T1 (sl) | Kombinirano zdravljenje raka | |
| IL260423B1 (en) | Methods and preparations for increasing the potency of super antigen-mediated cancer immunotherapy | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| GB201812647D0 (en) | Viral vectors and methods for the prevention or treatment of cancer | |
| IL266993A (en) | Combined therapy for cancer treatment | |
| IL267613A (en) | Pancreatic cancer treatment | |
| IL255169A0 (en) | Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer | |
| IL274748A (en) | Improved cancer treatment | |
| IL253642A0 (en) | Combined treatment for cancer | |
| IL262945A (en) | Medicament for treatment and/or prophylactic treatment of breast cancer | |
| GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer | |
| GB201717004D0 (en) | Methods of cancer therapy | |
| GB201711769D0 (en) | Methods of cancer therapy | |
| GB201704287D0 (en) | Treatment of cancer | |
| GB201703857D0 (en) | Treatment of cancer | |
| GB201702565D0 (en) | Treatment of cancer | |
| GB201704474D0 (en) | Combination therapy for treatment of cancer | |
| GB201622214D0 (en) | treatment of cancer |